NASDAQ:NVIV

InVivo Therapeutics - NVIV Stock Forecast, Price & News

$2.20

-0.09 (-3.93%)

(As of 01/27/2023 12:00 AM ET)

Add

Compare

Today's Range: $2.18
▼
$2.36
50-Day Range: $1.76
▼
$2.63
52-Week Range: $1.61
▼
$13.77

Volume: 59,700 shs
Average Volume: 67,244 shs
Market Capitalization: $4.21 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About InVivo Therapeutics (NASDAQ:NVIV) Stock

Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.

Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVIV Stock News Headlines

January 11, 2023 | benzinga.com

InVivo Therapeutics Hldg Stock (NASDAQ:NVIV), Quotes and News Summary

October 11, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

January 27, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

October 10, 2022 | marketwatch.com

InVivo Therapeutics Shares Continue Friday's Fall, Hit All-Time Intraday Low

October 7, 2022 | seekingalpha.com

InVivo Therapeutics dips 24% on $9M direct and private placement offerings

October 7, 2022 | marketwatch.com

InVivo Therapeutics Stock Drops on $9 Million Offering

October 7, 2022 | investorplace.com

Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?

October 7, 2022 | finance.yahoo.com

InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules

January 27, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

September 9, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference

August 28, 2022 | uk.finance.yahoo.com

InVivo Therapeutics Holdings Corp. (NVIV)

July 13, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

June 8, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery

June 2, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study

April 18, 2022 | finance.yahoo.com

Why Are InVivo Therapeutics Shares Trading Lower During Premarket Monday?

April 15, 2022 | nasdaq.com

Why InVivo Therapeutics Stock Falling?

April 14, 2022 | marketwatch.com

InVivo Therapeutics Announces 1-for-25 Reverse Stock Split

April 14, 2022 | finance.yahoo.com

InVivo Therapeutics stock sinks after 1-for-25 reverse stock split announced

April 14, 2022 | seekingalpha.com

InVivo Therapeutics slumps 7% on 1-for-25 reverse stock split

February 8, 2022 | finanznachrichten.de

Sidekick Health: DTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growth

February 8, 2022 | finance.yahoo.com

DTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growth

January 30, 2022 | fool.com

InVivo Therapeutics Holdings(NVIV)

January 6, 2022 | finance.yahoo.com

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference

December 29, 2021 | nasdaq.com

InVivo Therapeutics Holdings Corp Shares Fall 1.4% Below Previous 52-Week Low - Market Mover

December 29, 2021 | nasdaq.com

InVivo Therapeutics Holdings Corp Shares Close the Day 11.0% Lower - Daily Wrap

September 9, 2021 | finance.yahoo.com

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference

September 8, 2021 | finance.yahoo.com

InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NVIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVIV Company Calendar

Last Earnings: 11/07/2022
Today: 1/27/2023
Next Earnings (Estimated): 3/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NVIV
CUSIP: N/A
CIK: 1292519
Web: www.invivotherapeutics.com
Phone: (617) 863-5500
Fax: N/A
Employees: 6
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($8.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,900,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -78.11%
Return on Assets: -63.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.62
Quick Ratio: 4.62

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $13.22 per share
Price / Book: 0.17

Miscellaneous

Outstanding Shares: 1,915,000
Free Float: 1,903,000
Market Cap: $4.21 million
Optionable: Not Optionable
Beta: 0.76

Key Executives

Richard Toselli
President, Chief Executive Officer & Director

Richard C. Christopher
Chief Financial Officer & Treasurer

Heather M. Hamel
Chief Legal Officer & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

NVIV Stock - Frequently Asked Questions

How have NVIV shares performed in 2023?: InVivo Therapeutics' stock was trading at $2.35 at the start of the year. Since then, NVIV stock has decreased by 1.3% and is now trading at $2.32.
View the best growth stocks for 2023 here.
When is InVivo Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our NVIV earnings forecast.
How were InVivo Therapeutics' earnings last quarter?: InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) released its quarterly earnings results on Monday, November, 7th. The biotechnology company reported ($1.98) EPS for the quarter.
When did InVivo Therapeutics' stock split?: InVivo Therapeutics's stock reverse split on the morning of Wednesday, April 27th 2022. The 1-25 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of InVivo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV).
What is InVivo Therapeutics' stock symbol?: InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."
How do I buy shares of InVivo Therapeutics?: Shares of NVIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is InVivo Therapeutics' stock price today?: One share of NVIV stock can currently be purchased for approximately $2.32.
How much money does InVivo Therapeutics make?: InVivo Therapeutics (NASDAQ:NVIV) has a market capitalization of $4.44 million. The biotechnology company earns $-9,900,000.00 in net income (profit) each year or ($8.14) on an earnings per share basis.
How can I contact InVivo Therapeutics?: InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The official website for the company is www.invivotherapeutics.com. The biotechnology company can be reached via phone at (617) 863-5500 or via email at info@invivotherapeutics.com.

This page (NASDAQ:NVIV) was last updated on 1/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial